New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
10:04 EDTASH, COG, GMAN, MWV, MGLN, KRA, SWN, ZIOP, TWOOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Ashland (ASH) downgraded to Neutral from Buy at Longbow... Cabot Oil & Gas (COG) downgraded to Hold from Buy at Stifel... Gordmans Stores (GMAN) downgraded to Neutral from Overweight at Piper Jaffray... Kraton Performance (KRA) downgraded to Perform from Outperform at Oppenheimer... Magellan Health (MGLN) downgraded to Market Perform from Outperform at Raymond James... MeadWestvaco (MWV) downgraded to Neutral from Buy at UBS... Southwestern Energy (SWN) downgraded to Hold from Buy at Stifel... Ziopharm (ZIOP) downgraded to Underperform from Market Perform at BMO Capital... Two Harbors (TWO) downgraded to Neutral from Buy at Compass Point... Cabot Oil & Gas (COG) downgraded to Hold from Buy at Stifel... Southwestern Energy (SWN) downgraded at Stifel.
News For ASH;COG;GMAN;MWV;MGLN;KRA;SWN;ZIOP;TWO From The Last 14 Days
Check below for free stories on ASH;COG;GMAN;MWV;MGLN;KRA;SWN;ZIOP;TWO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 30, 2014
17:46 EDTKRAKraton Performance sees FY14 adjusted EPS $1.40-$1.50, consensus $1.62
Subscribe for More Information
17:44 EDTKRAKraton Performance reports Q2 adjusted EPS 46c, consensus 52c
Reports Q2 revenue $323.8M, consensus $342.61M. Cariflex sales revenue was $29.2M for the three months ended June 30. Advanced Materials sales revenue was $81.7M for the three months ended June 30. Adhesives, Sealants and Coatings sales revenue was $128.2M for the three months ended June 30. Paving and Roofing sales revenue was $84.6M for the three months ended June 30.
07:29 EDTMWVMeadWestvaco aims to continue cost reduction efforts in Q3
The company said, "The principal benefits that are expected to drive the companyís improvement in the third quarter are increases in packaging volumes, especially bleached paperboard and plastic dispensing solutions across major end-markets, ongoing value-based pricing initiatives across all packaging businesses, productivity improvements and continued positive operating leverage from increased mill and plant utilization rates and continuing cost reduction efforts, including growing benefits from the companyís margin improvement program."
07:28 EDTMWVMeadWestvaco sees Q3 EPS ex-items above year-ago levels
The company said, "For Q3, earnings excluding special items are expected to be above year-ago levels on a continuing operations basis. The company expects ongoing benefits from its commercial and operational excellence strategies, as well as continued contributions from its growth and productivity investments and cost savings initiatives." Q3 EPS consensus 61c.
07:27 EDTMWVMeadWestvaco reports Q2 EPS ex-items 53c, consensus 50c
Reports Q2 revenue $1.47B, consensus $1.45B. Reports Q2 EPS from continuing operations 43c.
July 29, 2014
15:53 EDTMWVNotable companies reporting before tomorrow's open
Subscribe for More Information
July 28, 2014
10:02 EDTCOGOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AcelRx (ACRX) downgraded to Hold from Buy at Canaccord... Anglo American (AAUKY) downgraded to Neutral from Buy at UBS... Aon plc (AON) downgraded to Hold from Buy at Sandler ONeill... Cabot Oil & Gas (COG) downgraded at Oppenheimer... Cisco (CSCO) downgraded to Sector Perform from Outperform at Pacific Crest... Coeur Mining (CDE) downgraded to Market Perform from Outperform at Raymond James... DSW (DSW) downgraded at Sterne Agee... DuPont Fabros (DFT) downgraded to Neutral from Buy at Citigroup... El Paso Electric (EE) downgraded to Hold from Buy at Jefferies... Enphase Energy (ENPH) downgraded to Hold from Buy at Deutsche Bank... GlaxoSmithKline (GSK) downgraded to Neutral from Buy at BofA/Merrill... Horizon Technology (HRZN) downgraded to Hold from Buy at Wunderlich... Lear (LEA) downgraded to Hold from Buy at Deutsche Bank... Life Time Fitness (LTM) downgraded at Wedbush... Monster Beverage (MNST) downgraded to Neutral from Buy at UBS... NRG Energy (NRG) downgraded to Buy from Conviction Buy at Goldman... PG&E (PCG) downgraded to Sell from Neutral at Goldman... Pfizer (PFE) downgraded at BMO Capital... Post Properties (PPS) downgraded to Neutral from Buy at Citigroup... Publicis (PUBGY) downgraded to Sell from Neutral at Citigroup... Selmer Scientific (SMLR) downgraded to Hold from Buy at Aegis... TransCanada (TRP) downgraded to Neutral from Outperform at Credit Suisse... Travelers (TRV) downgraded to Hold from Buy at Sandler O'Neill... Zurich Insurance (ZURVY) downgraded to Underperform from Market Perform at Bernstein.
08:17 EDTMGLNMCO sell-off provides buying opportunity, says Leerink
Subscribe for More Information
07:44 EDTCOGCabot Oil & Gas downgraded at Oppenheimer
Subscribe for More Information
07:13 EDTCOGCabot Oil & Gas downgraded to Perform from Outperform at Oppenheimer
July 25, 2014
10:02 EDTCOGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:44 EDTMGLNMagellan Health sees FY14 adjusted EPS $2.67-$3.32, consensus $2.40
Sees FY14 segment profit $238M-$258M; Sees FY14 cash flow from operations $204M-$226M
06:43 EDTMGLNMagellan Health reports Q2 adjusted EPS 39c, consensus 57c
Subscribe for More Information
06:07 EDTCOGCabot Oil & Gas downgraded to Neutral from Outperform at RW Baird
RW Baird downgraded Cabot Oil & Gas to Neutral following the company's Q2 results saying realizations is likely to limit near-term upside. The firm has a $43 price target for shares.
July 24, 2014
08:12 EDTASHAshland reinstated as a Conviction Buy from Not Rated at Goldman
Subscribe for More Information
07:44 EDTCOGCabot Oil & Gas reports Q2 Marcellus Shale averaged 1,258 Mmcf per day
Subscribe for More Information
07:43 EDTCOGCabot Oil & Gas reports Q2 production of 127.6 Bcfe
Reports Q2 liquids production of 961,000 barrels, an increase of 26% over last year's comparable quarter as reported; Reports Q2 crude oil and condensate production of 869,000 barrels, an increase of 25% over last year's comparable quarter as reported; Natural gas price realizations, including the effect of hedges, were $3.47 per thousand cubic feet in Q2. the impact of hedges, natural gas price realizations for the quarter were $3.78 per Mcf. Total per unit costs decreased to $2.59 per Mcfe in the second quarter of 2014, down 16 percent from $3.10 per Mcfe in the second quarter of 2013.
07:42 EDTCOGCabot Oil & Gas reports Q2 adjusted EPS 28c, consensus 25c
Subscribe for More Information
July 23, 2014
08:15 EDTCOGCabot Oil & Gas price target lowered to $43 from $52 at RW Baird
Subscribe for More Information
July 22, 2014
07:15 EDTZIOPZiopharm announces expansion of oncology programs with Intrexon
Ziopharm (ZIOP) announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon (XON) to include chimeric antigen receptor T-cell, or CAR-T, therapy. Additionally the company has provided an update on its development efforts with the proprietary RheoSwitch Therapeutic System, or RTS, platform, an inducible regulator for expression of therapeutic molecules through administration of an oral activator ligand, as well as its clinical program with Ad-RTS-IL-12, a novel DNA-based therapeutic candidate for the controlled expression of IL-12. CAR-T cells represent an emerging, high value immunological therapy that can target and destroy cancer cells displaying "personalized" fingerprints, yet current approaches feature challenges associated with toxicity, off-target effects, and uneconomical manufacturing. Intrexon possesses the integrated technology platforms, molecular engineering, systems biology, and cell engineering capabilities required to overcome these challenges and fully realize the potential of CARĀ]T cell therapies. Most significantly, utilization of the RTS platform will facilitate exquisite regulation of one or more bioeffectors in CAR-T cells enabling physicians to control systemic effects of cell therapies with an appropriate dosing regimen of the oral activator ligand, and eventually bring about improved safety and efficacy of these and related therapeutic strategies. Further preclinical work is underway in this promising area of study, and ZIOPHARM and Intrexon expect to provide a progress update in the second half of 2014.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use